Exploiting the therapeutic vulnerability of IDH-mutant gliomas with zotiraciclib
Y. Pang, Q. Li, Z. Sergi, G. Yu, X. Sang, O. Kim, H. Wang, A. Ranjan, M. Merchant, B. Oudit, R. W. Robey, F. Soheilian, B. Tran, F. J. Nunez, M. Zhang, , J. Wu
This paper identifies zotiraciclib as a therapeutic agent targeting IDH-mutant gliomas by disrupting mitochondrial function and inducing oxidative stress, leading to a clinical trial.
bioRxiv · Jun 29, 2023Cancer Biology